Agios Pharmaceuticals Shares Rise on Strong Q1 Earnings and Aqvesme Launch Progress
Shares of Agios Pharmaceuticals rose by 11.2% this week following strong first-quarter earnings driven by the successful U.S. commercial launch of its drug, Aqvesme. The company also provided updates on its pipeline for treating sickle cell disease and myelodysplastic syndromes.
Topics: drug approvals earnings pharmaceuticals pipeline progress stock performance